Evidence map›Paper›PMID 32140397›Full record

ArticleActa pharmaceutica Sinica. B2020

Targeting peptide-decorated biomimetic lipoproteins improve deep penetration and cancer cells accessibility in solid tumor.

Tao Tan, Yuqi Wang, Jing Wang, Zhiwan Wang, Hong Wang, Haiqiang Cao, Jie Li, Yaping Li, Zhiwen Zhang, Siling Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tao TanSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuqi WangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jing WangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhiwan WangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hong WangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Haiqiang CaoState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jie LiState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yaping LiState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhiwen ZhangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Siling WangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CNShenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limited penetration of nanoparticles and their poor accessibility to cancer cell fractions in tumor remain essential challenges for effective anticancer therapy. Herein, we designed a targeting peptide-decorated biomimetic lipoprotein (termed as BL-RD) to enable their deep penetration and efficient accessibility to cancer cell fractions in a tumor, thereby improving the combinational chemo-photodynamic therapy of triple negative breast cancer. BL-RD was composed of phospholipids, apolipoprotein A1 mimetic peptide (PK22), targeting peptide-conjugated cytotoxic mertansine (RM) and photodynamic agents of DiIC18(5) (DiD). The counterpart biomimetic lipoprotein system without RM (termed as BL-D) was fabricated as control. Both BL-D and BL-RD were nanometer-sized particles with a mean diameter of less than 30 nm and could be efficiently internalized by cancer cells. After intravenous injection, they can be specifically accumulated at tumor sites. When comparing to the counterpart BL-D, BL-RD displayed superior capability to permeate across the tumor mass, extravasate from tumor vasculature to distant regions and efficiently access the cancer cell fractions in a solid tumor, thus producing noticeable depression of the tumor growth. Taken together, BL-RD can be a promising delivery nanoplatform with prominent tumor-penetrating and cancer cells-accessing capability for effective tumor therapy.

Indexed as

4T1-GFP, 4T1 cancer cells with stable expression of green fluorescence proteinApoA1, apolipoprotein A1BL-D, biomimetic lipoprotein system without targeting peptideBL-RD, targeting peptide decorated biomimetic lipoprotein systemCAF, cancer-associated fibroblastsCancer therapyCLSM, confocal laser scanning microscopyDAPI, 4′,6-diamidino-2-phenylindoleDCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetateDiD, DiIC18(5)DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholineDrug deliveryEC, endothelial cellsECM, extracellular matrixEE, encapsulation efficiencyFBS, fetal bovine serumGSH, glutathioneHDL, high density lipoproteinH&E staining, hematoxylin-eosin stainingHPLC, high performance liquid chromatographyIC50, half-inhibitory concentrationLipo-D, liposome system without targeting peptideLipoproteinLipo-RD, targeting peptide decorated biomimetic lipoprotein systemMCS, multicellular spheroidsMTT, thiazolyl blue tetrazolium bromideNanoparticlesPBS, phosphate buffered solutionPDT, photodynamic therapyRM, targeting peptide-conjugated cytotoxic mertansineROS, reactive oxygen speciesSOSG, singlet oxygen sensor greenTAM, tumor-associated macrophageTEM, transmission electronic microscopeTGI, tumor growth indexTumor penetrationα-SMA, α-smooth muscle actin

Identifiers

PMID32140397
PMCPMC7049576
OpenAlexW2948124195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.